Breaking News

AMRI, Codexis in Technology Alliance

February 13, 2013

Aims to improve manufacturing routes for selected APIs

AMRI and Codexis have entered into a two-year SMARTSOURCING partnership that will combine the companies' capabilities and technologies for specific customer projects, with the goal of potentially lower costs, greater yields, cleaner processes and/or faster turnaround times.
 
The companies aim to identify and implement new and improved manufacturing routes for selected APIs by combining Codexis' directed evolution technology, which enables rapid enzyme discovery and optimization, with AMRI's process development and manufacturing capabilities, including its microbial strains.
 
"We are pleased to announce this partnership with Codexis, a company that shares our philosophy of prioritizing scientific problem solving, innovation and customer service," said AMRI's chairman, president and chief executive officer, Thomas E. D'Ambra, Ph.D. "Combining AMRI's expertise in chemistry, biocatalysis, quality assurance and manufacturing with Codexis' cutting-edge biocatalysis technology and services, creates a proprietary advantage to our customer's development projects. This is another example of the AMRI SMARTSOURCING™ strategy of creating partnerships to deliver better outcomes to our customers."
 
"Codexis selected AMRI for this collaboration because AMRI understands the opportunity to use biocatalysis for effective and comprehensive route assessment and manufacturing," said Dr. Peter Seufer-Wasserthal, senior vice president Pharmaceuticals, Codexis. "Both companies have established strong reputations in the pharmaceutical manufacturing industry. By working together, AMRI and Codexis should identify more opportunities, which will benefit both companies and their customers by developing innovative, cost-effective and practical chemical processes."

Related Contract Manufacturing:

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.